Training
5 pages in this section, most recently updated September 4, 2026.
- 01
Resistance training on a GLP-1: the minimum that works, how to start, and how to progress
What the physical activity guidelines and the 2025 joint advisory ask for, what the meta-analyses show about protein plus lifting, a two-to-three-day starting programme with progression rules, and the safety notes specific to therapy.
Updated September 4, 2026
- 02
Fat versus lean: what the STEP 1 and SURMOUNT-1 DXA substudies actually measured
The body-composition numbers from the semaglutide and tirzepatide pivotal trials, what share of the weight lost was lean tissue, how that compares with other weight loss, what lean mass includes, and what the evidence says changes the ratio.
Updated September 4, 2026
- 03
Exercising when nauseated: what to keep, what to drop, and when to stop
Nausea is the most common adverse reaction on GLP-1 therapy and clusters around dose escalation. How to keep training through it without making it worse, the hydration and glucose warnings that apply, and the symptoms that mean stop and call.
Updated September 4, 2026
- 04
Aerobic activity and daily steps: the guideline numbers, the step-count evidence, and what the trials asked
The 150 to 300 minute guideline and where it comes from, the 2022 meta-analysis on daily steps and mortality, why aerobic exercise alone does not protect lean mass, and how to fit it around a GLP-1's side effects.
Updated September 4, 2026
- 05
Exercise plus a GLP-1: what the randomised trials show, and what nobody has tested yet
S-LiTE, the only large randomised trial to combine a GLP-1 with a structured exercise programme, Villareal's trial of exercise type during weight loss, what they show about additive effects and body composition, and the gaps that remain for semaglutide and tirzepatide.
Updated September 4, 2026